Al-Hammadi’s 2014 net profit up 16% to SAR 129 mln
Al-Hammadi Development and Investment Company, a newly listed company, reported 2014’s net profit of SAR 129 million, a 16 percent increase compared to the last year.
A net profit of SAR 33.7 million was reported for Q4-2014 compared to SAR 25.4 million for Q3.
Financials (M)
Item | 2013 | 2014 | Change |
---|---|---|---|
Revenues | 434.08 | 481.96 | 11.0 % |
Gross Income | 185.16 | 209.11 | 12.9 % |
Operating Income | 112.10 | 130.95 | 16.8 % |
Net Income | 111.50 | 128.95 | 15.6 % |
Average Shares | 160.00 | 160.00 | - |
EPS (Riyals) | 0.70 | 0.81 | 15.6 % |
The Company attributed the increase of 2014’s net profit compared to the same period last year to the growth of revenue income driven by the growth of the number patients as well as improving the operating efficiency.
Current Quarter Comparison (M)
Item | Q4 2013 | Q4 2014 | Change |
---|---|---|---|
Revenues | 124.13 | 129.43 | 4.3 % |
Gross Income | 55.17 | 55.99 | 1.5 % |
Operating Income | 34.34 | 34.52 | 0.5 % |
Net Income | 33.29 | 33.71 | 1.2 % |
Average Shares | 160.00 | 160.00 | - |
EPS (Riyals) | 0.21 | 0.21 | 1.2 % |
View other reports
Share Price
Al Hammadi Holding (ALHAMMADI)
Current | |
Market Cap (M Riyal) | 6,400.00 |
Enterprise Value (EV) (M) | 6,340.52 |
Shares Outstanding ((M)) | 160.00 |
EPS ( Riyal) (TTM) | 2.04 |
Book Value (BV) ( Riyal) | 12.11 |
Par Value ( Riyal) | 10.00 |
Adjusted P/E (Last12) | 24.20 |
P/E (TTM) | 19.62 |
Price/book | 3.30 |
Return on Average Assets (%) (TTM) | 12.6 |
Return on Average Equity (%) (TTM) | 17.3 |
Financial results (Million)
Period | Revenues | Change | Gross Income | Change | Operating Income | Change |
---|---|---|---|---|---|---|
Q1 2014 | 122.04 | 16.4 % | 54.71 | 15.6 % | 35.96 | 19.5 % |
Q2 2014 | 121.66 | 11.8 % | 53.68 | 17.1 % | 35.77 | 57.3 % |
Q3 2014 | 108.83 | 13.1 % | 44.74 | 21.5 % | 24.77 | 30.3 % |
Q4 2014 | 129.43 | 4.3 % | 55.99 | 1.5 % | 34.52 | 0.5 % |
2014 | 481.96 | 11.0 % | 209.11 | 12.9 % | 130.95 | 16.8 % |
Profit Performance (Million)
Period | Net Income | Change | EPS(Riyal) | Extraordinary Income/Expense | Net Profit Before Unusual Items | EPS Before XO Items |
---|---|---|---|---|---|---|
Q1 2014 | 34.23 | 14.7 % | 0.21 | - | 34.23 | 0.21 |
Q2 2014 | 35.60 | 18.4 % | 0.22 | - | 35.60 | 0.22 |
Q3 2014 | 25.42 | 38.7 % | 0.16 | - | 25.42 | 0.16 |
Q4 2014 | 33.71 | 1.2 % | 0.21 | - | 33.71 | 0.21 |
2014 | 128.95 | 15.6 % | 0.81 | - | 128.95 | 0.81 |
Profitability
Period | Gross Margin | OIBDA Margin | Net Margin Before Unusual Items |
---|---|---|---|
Q1 2014 | 42.66 % | 27.85 % | 24.35 % |
Q2 2014 | 43.18 % | 29.90 % | 26.17 % |
Q3 2014 | 43.70 % | 30.34 % | 26.97 % |
Q4 2014 | 43.39 % | 30.09 % | 26.75 % |
2014 | 43.39 % | 30.07 % | 26.75 % |
Compared With The
Per Share Data (Riyal)
Period | Shares Outstanding (M) | EPS (Riyal) | Adjusted EPS (Riyal) | Book Value (BV) |
---|---|---|---|---|
Q1 2014 | 160.00 | 0.72 | 0.69 | 3.87 |
Q2 2014 | 160.00 | 0.76 | 0.76 | 7.88 |
Q3 2014 | 160.00 | 0.80 | 0.80 | 8.04 |
Q4 2014 | 160.00 | 0.81 | 0.81 | 8.25 |
Multiple Ratios (End of Period Price)
Period | P/E | Adjusted P/E | Price/book |
---|---|---|---|
Q1 2014 | - | - | - |
Q2 2014 | - | - | - |
Q3 2014 | 51.42 | 51.42 | 5.14 |
Q4 2014 | 48.92 | 48.92 | 4.78 |
Business Segments (Million)
2014
Period | healthy services and other | Pharmaceutical sales revenue - Pharmacies |
---|
Call Request
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}